RxDoctor Payments Data

Steven Kornberg, MD

Cardiovascular Disease · Somers Point, NJNPI 1427089069

Payments from drug & device makers

$913in general payments, 2019–2025

Across 29 payments — averaging $31.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$409
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$132
  • Impulse Dynamics (USA) Inc.$100
  • Johnson & Johnson$89
  • Abbott$66
  • Novartis$49
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$913 in reported general payments places this provider in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$93,282
Medicare patients
534
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$99,238
XareltoRivaroxaban15$21,696
Praluent PenAlirocumab16$11,145
Nebivolol Hcl24$2,101
Atorvastatin Calcium112$1,611
Amiodarone Hcl15$1,308
Metoprolol Succinate57$1,046
Rosuvastatin Calcium32$1,015
Flecainide Acetate15$976
Losartan Potassium32$387
Ezetimibe22$343
ClopidogrelClopidogrel Bisulfate24$341
Lisinopril37$334
Amlodipine Besylate42$290
Metoprolol Tartrate26$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$99,23870 claims
Johnson & JohnsonXarelto$89$21,69615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →